The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

Sehn, Laurie H.; Berry, Brian; Chhanabhai, Mukesh; Fitzgerald, Catherine; Gill, Karamjit; Hoskins, Paul; Klasa, Richard; Savage, Kerry J.; Shenkier, Tamara; Sutherland, Judy; Gascoyne, Randy D.; Connors, Joseph M.

doi:10.1182/blood-2006-08-038257

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous entity, with patients exhibiting a wide range of outcomes. The addition of rituximab to CHOP chemotherapy (R-CHOP)has led to a marked improvement in survival and has called into question the significance of previously recognized prognostic …